Teva Pharmaceutical Industries Ltd. (TEVA) Dividend Summary
TEVA Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals. Teva USA sells its products to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies. The company markets a variety of dosage forms, including both extended and immediate release tablets and capsules, creams, ointments, solutions, and suspensions. Key therapeutic areas are the analgesic, anti-infective, cardiovascular, CNS, dermatological and anti-inflammatory categories.
Last update 07/27/2010
Dividend Yield Summary
| |
2009 |
2008 |
2009 |
2010 |
2011 |
2012 |
| Dividends |
$0.45 |
$0.43 |
$0 |
$0 |
$0 |
$0 |
| Price |
$51.72 |
$40.95 |
$0 |
$0 |
$0 |
$0 |
| Yield |
0.87 % |
1.05 % |
0 % |
0 % |
0 % |
0 % |
Earnings Information
| Next Report Date |
11/05/2009 |
| Estimated EPS (year) |
$3.35 |
| Estimated EPS (quarter) |
$0.88 |
| Estimated EPS Growth |
20.15% |
| Payout Ratio |
0.14% |
| Payout change vs. 5 year average |
0.00% |
Dividend/Split History
| Date |
Amount Per Share/Split Ratio |
Type |
| 2010-03-10 |
$0.18000 |
Dividend |
| 2009-08-20 |
$0.15000 |
Dividend |
| 2009-03-12 |
$0.14000 |
Dividend |
| 2008-11-27 |
$0.11000 |
Dividend |
| 2008-08-27 |
$0.10400 |
Dividend |
| 2008-08-20 |
$0.13000 |
Dividend |
| 2008-05-29 |
$0.13000 |
Dividend |
| 2008-02-15 |
$0.12500 |
Dividend |
| 2007-11-02 |
$0.10100 |
Dividend |
| 2007-08-10 |
$0.09200 |
Dividend |
| 2007-05-10 |
$0.09800 |
Dividend |
| 2007-02-16 |
$0.09400 |
Dividend |
| 2006-11-10 |
$0.07900 |
Dividend |
| 2006-08-11 |
$0.07800 |
Dividend |
| 2006-05-12 |
$0.07700 |
Dividend |
| 2006-03-06 |
$0.07200 |
Dividend |
| 2005-11-10 |
$0.06400 |
Dividend |
| 2005-08-11 |
$0.06700 |
Dividend |
| 2005-05-05 |
$0.06900 |
Dividend |
| 2005-02-17 |
$0.06900 |
Dividend |
Company Profile
TEVA Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals. Teva USA sells its products to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies. The company markets a variety of dosage forms, including both extended and immediate release tablets and capsules, creams, ointments, solutions, and suspensions. Key therapeutic areas are the analgesic, anti-infective, cardiovascular, CNS, dermatological and anti-inflammatory categories. TEVA PHARM ADR 5 Basel Street P.O. Box 3190 Petach Tikva, 49131, ISR Phone: 972 3 926 7267 Fax: 972 3 926 7472 Web: www.tevapharm.com Email: Key Information
| Sector: |
Medical |
| Industry: |
DRUGS |
| Analysts |
20 |
| Fiscal Year End: |
December |
| Next Reported Fiscal Year: |
2008 |
| Last Reported Quarter: |
6/30/2009 |
Management
| Presi.; C.E.O. |
Israel Makov |
| V.P.; Chief Tech. Off. |
Rodney Kasan |
| V.P.; Intl. Pharm. Sales |
Aharon Agmon |
| V.P.; Human Resources |
Haim Benjamini |
| C.F.O. |
Dan S. Suesskind |
Competitors
SIC Code: 2834
| Ticker |
Company Name |
| WPI |
WATSON PHARMA |
| RDY |
DOCTOR REDDYS |
| PRX |
PAR PHARMA COS |
| CPD |
CARACO PHARM |
| SCR |
SIMCERE PHARMAC |
| IPXL |
IMPAX LABORATRS |
| HITK |
HI TECH PHARMA |
Teva Pharmaceutical Industries Ltd. TEVA (NSDQ) Financial Ratios
| P/E |
| Current FY Estimate |
15.47 |
| Trailing 12 Months |
17.18 |
| PEG Ratio |
0.77 |
|
| EPS Growth |
| vs. Previous Year |
27.69% |
| vs. Previous Quarter |
16.90% |
|
| Sales Growth |
| vs. Previous Year |
20.44% |
| vs. Previous Quarter |
8.04% |
|
| Price Ratios |
| Price/Book |
2.55 |
| Price/Cash Flow |
16.08 |
| Price/Sales |
3.71 |
|
| ROE |
| 06/30/2009 |
16.05 |
| 03/30/2009 |
15.45 |
| 12/30/2008 |
15.19 |
|
| ROA |
| 06/30/2009 |
8.53 |
| 03/30/2009 |
8.36 |
| 12/30/2008 |
8.56 |
|
| Current Ratio |
| 06/30/2009 |
1.52 |
| 03/30/2009 |
1.30 |
| 12/30/2008 |
1.35 |
|
| Quick Ratio |
| 06/30/2009 |
1.04 |
| 03/30/2009 |
0.93 |
| 12/30/2008 |
0.95 |
|
| Operating Margin |
| 06/30/2009 |
21.32 |
| 03/30/2009 |
20.64 |
| 12/30/2008 |
20.76 |
|
| Net Margin |
| 06/30/2009 |
7.53 |
| 03/30/2009 |
8.05 |
| 12/30/2008 |
5.73 |
|
| Pre-Tax Margin |
| 06/30/2009 |
8.93 |
| 03/30/2009 |
9.11 |
| 12/30/2008 |
7.46 |
|
| Book Value |
| 06/30/2009 |
20.38 |
| 03/30/2009 |
18.04 |
| 12/30/2008 |
18.34 |
|
| Inventory Turnover |
| 06/30/2009 |
1.79 |
| 03/30/2009 |
2.32 |
| 12/30/2008 |
3.27 |
|
| Debt-to-Equity |
| 06/30/2009 |
0.26 |
| 03/30/2009 |
0.31 |
| 12/30/2008 |
0.34 |
|
| Debt-to-Capital |
| 06/30/2009 |
21.06 |
| 03/30/2009 |
24.09 |
| 12/30/2008 |
25.56 |
|
Quick Quote
Updated as of 4:00pm
| Last Trade: |
53.12 |
| Trade Time: |
4:00pm |
| Change: |
0.00 |
| Open: |
N/A |
| High: |
N/A |
| Low: |
N/A |
| Volume: |
0 |
Security Details
| Exchange |
NSDQ |
| CUSIP |
|
| Split Date |
07/01/2004 |
| Split Factor |
2 |
| Shares outstanding |
874.00 |
| Beta |
0.21 |
Detailed Quote as of 09/22/2009
| Price |
$51.88 |
| 52 Week High |
$54.25 |
| 52 Week Low |
$37.78 |
| Price Change (4 weeks) |
$0.66 |
| Price Change (12 weeks) |
$6.75 |
| Price Change (YTD) |
$21.87 |
| Price Change (4 weeks) vs. S&P |
$-3.31 |
| Price Change (12 weeks) vs. S&P |
$-8.18 |
| Price Change (YTD) vs. S&P |
$3.04 |
| Average Daily Volume (20 Days) |
4,420,460 |
| Market Capitalization |
$45,343.10 |
Price History
Earning Announcement
| Last Confirmation Date |
2010-07-07 |
| Next Earnings Announcement Date |
2010-07-27 |
| Earnings Quarter |
Q2 |
| Announcement Status |
Confirmed |
Investor Conference Call
Last Dividend Payout
| Announcement Date |
2010-02-16 |
| Record Date |
2010-02-23 |
| Pay Date |
2010-03-10 |
| Amount Per Share |
$0.18 |
Board Shareholder Meeting
| First Quarter |
2008-05-06 |
| Second Quarter |
2008-07-29 |
| Third Quarter |
2007-10-30 |
| Fourth Quarter |
2008-02-12 |
|
